Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Incidence, Diagnosis and Prognosis of Cardiac Amyloidosis

  • Lee, Min-Ho (Cardiovascular Center, Seoul National University Hospital) ;
  • Lee, Seung-Pyo (Cardiovascular Center, Seoul National University Hospital) ;
  • Kim, Yong-Jin (Cardiovascular Center, Seoul National University Hospital) ;
  • Sohn, Dae-Won (Cardiovascular Center, Seoul National University Hospital)
  • Received : 2013.03.13
  • Accepted : 2013.09.25
  • Published : 2013.11.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: Cardiac involvement is frequent in systemic amyloidosis and is the most important determinant of the clinical outcome. The aims of this study were to assess the incidence and prognosis of cardiac amyloidosis and discuss the diagnostic issues related to cardiac amyloidosis. Subjects and Methods: We retrospectively studied all patients diagnosed with systemic amyloidosis who presented to our institution from January 1999 to December 2011. Results: Of the 129 patients with systemic amyloidosis, cardiac amyloidosis was diagnosed in 62 patients. At the 3 years' follow-up of the patients with systemic amyloidosis, there was a statistically significant difference in mortality between patients with cardiac amyloidosis and the rest of the patients (58.1% vs. 37.3%, p=0.008). In the Cox proportional hazard model, old age {hazard ratio (HR) 18.336, p=0.006}, elevation of cardiac troponin I (cTNI) (HR 13.246, p=0.020), left ventricular (LV) systolic dysfunction (HR 5.137, p=0.041) and diastolic dysfunction (HR 64.595, p=0.022) were independently associated with survival in cardiac amyloidosis. In the diagnosis of monoclonal gammopathy, serum or urine protein electrophoresis was not sensitive enough to be used clinically compared to serum free light chain assay (35.8% vs. 96.4%). Conclusion: In systemic amyloidosis, cardiac involvement was the most important determinant of the prognosis, and old age, elevation of cTNI, LV systolic dysfunction and diastolic dysfunction were independently associated with survival in cardiac amyloidosis.

Keywords

References

  1. Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 2004;255:159-78. https://doi.org/10.1046/j.1365-2796.2003.01262.x
  2. Westermark P, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature -- 2002. Amyloid 2002;9:197-200. https://doi.org/10.3109/13506120209114823
  3. Duston MA, Skinner M, Shirahama T, Cohen AS. Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years' experience. Am J Med 1987;82:412-4. https://doi.org/10.1016/0002-9343(87)90439-6
  4. Klein AL, Hatle LK, Burstow DJ, et al. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1989;13:1017-26. https://doi.org/10.1016/0735-1097(89)90254-4
  5. Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008; 51:1022-30. https://doi.org/10.1016/j.jacc.2007.10.049
  6. Perugini E, Rapezzi C, Piva T, et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006;92:343-9.
  7. Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 2002;9:108-14.
  8. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-28. https://doi.org/10.1002/ajh.20381
  9. Kyle RA, Greipp PR, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood 1986;68: 220-4.
  10. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001;19:3350-6. https://doi.org/10.1200/JCO.2001.19.14.3350
  11. Falk RH, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med 2000;45:107-37.
  12. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91:141-57. https://doi.org/10.1093/qjmed/91.2.141
  13. Morris KL, Tate JR, Gill D, et al. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Intern Med J 2007;37:456-63. https://doi.org/10.1111/j.1445-5994.2007.01368.x
  14. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy- proven cardiac involvement. Am J Cardiol 2005;95:535-7. https://doi.org/10.1016/j.amjcard.2004.10.028
  15. Cueto-Garcia L, Tajik AJ, Kyle RA, et al. Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. Mayo Clin Proc 1984;59:589-97. https://doi.org/10.1016/S0025-6196(12)62409-4
  16. Klein AL, Hatle LK, Taliercio CP, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1990;16:1135-41. https://doi.org/10.1016/0735-1097(90)90545-Z
  17. Hamer JP, Janssen S, van Rijswijk MH, Lie KI. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J 1992;13:623-7. https://doi.org/10.1093/oxfordjournals.eurheartj.a060225
  18. Rahman JE, Helou EF, Gelzer-Bell R, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 2004;43:410-5. https://doi.org/10.1016/j.jacc.2003.08.043
  19. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 1982; 49:9-13. https://doi.org/10.1016/0002-9149(82)90270-3
  20. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010;3:155-64. https://doi.org/10.1016/j.jcmg.2009.09.023
  21. Kristen AV, Perz JB, Schonland SO, et al. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail 2007;9:617-24. https://doi.org/10.1016/j.ejheart.2007.01.012
  22. Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983;58:665-83.
  23. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93. https://doi.org/10.7326/0003-4819-140-2-200401200-00008
  24. Seldin DC, Anderson JJ, Sanchorawala V, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004;104:1888-93. https://doi.org/10.1182/blood-2004-01-0089
  25. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541-9. https://doi.org/10.1200/JCO.2011.37.7614
  26. Klein AL, Hatle LK, Taliercio CP, et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 1991;83:808-16. https://doi.org/10.1161/01.CIR.83.3.808
  27. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84. https://doi.org/10.1046/j.1365-2141.2003.04433.x
  28. Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107:3854-8. https://doi.org/10.1182/blood-2005-11-4385
  29. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003;361:1787-9. https://doi.org/10.1016/S0140-6736(03)13396-X
  30. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol 1997;30:8-18. https://doi.org/10.1016/S0735-1097(97)00144-7

Cited by

  1. Visual Assessment of Relative Apical Sparing Pattern Is More Useful Than Quantitative Assessment for Diagnosing Cardiac Amyloidosis in Borderline or Mildly Increased Left Ventricular Wall Thickness. vol.79, pp.7, 2013, https://doi.org/10.1253/circj.cj-14-1328
  2. Pericardial Effusion and Multiple Organ Involvement Are Independent Predictors of Mortality in Patients with Systemic Light Chain Amyloidosis vol.54, pp.15, 2015, https://doi.org/10.2169/internalmedicine.54.3500
  3. Isolated Tricuspid Regurgitation: Initial Manifestation of Cardiac Amyloidosis vol.48, pp.6, 2013, https://doi.org/10.5090/kjtcs.2015.48.6.422
  4. De Novo AL Amyloidosis in a Renal Allograft vol.90, pp.6, 2013, https://doi.org/10.3904/kjm.2016.90.6.545
  5. Diagnosis and Management of a Cardiac Amyloidosis Case Mimicking Hypertrophic Cardiomyopathy vol.10, pp.12, 2013, https://doi.org/10.7759/cureus.3749
  6. Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy ― A Single-Center Cohort Study of 227 Patients ― vol.83, pp.4, 2013, https://doi.org/10.1253/circj.cj-18-1048
  7. Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States vol.12, pp.6, 2013, https://doi.org/10.1161/circheartfailure.118.005407
  8. Amyloid cardiomyopathy in the elderly: clinical options, difficulties in diagnosis and treatment vol.26, pp.1, 2013, https://doi.org/10.18821/0869-2106-2020-26-1-45-66
  9. Kardiale Amyloidose - Skelettszintigrafie und Amyloidspezifische PET-Tracer vol.13, pp.3, 2020, https://doi.org/10.1055/a-1218-4419
  10. The Role of Light Kappa and Lambda Chains in Heart Function Assessment in Patients with AL Amyloidosis vol.10, pp.6, 2013, https://doi.org/10.3390/jcm10061274